GMED

Globus Medical Inc. Class A Common Stock (GMED) | Rumor.io

Globus Medical

GMED

Attention (50-day avg)0%

Attention rank (50-day avg)#1,273

Bullish sentiment (50-day avg)78%

Price to earnings ratio19.1

Market capitalization10.2B

Earnings per share3.91

Dividend yield (TTM)—

Revenue (annual)2.9B

Net income (annual)537.9M

Social

What share of all stock conversation is about GMED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Feb 24

Globus Medical (GMED) reported Q4 2025 earnings, beating revenue estimates with $826.4M sales and issuing full-year guidance of $3.2B.
The company's base business grew 10.6% and total revenue grew 26%, with GAAP EPS of $1.05, up 452.63% YoY.
GMED reaffirmed its full-year 2026 revenue guidance of $3.18B and updated its non-GAAP diluted EPS guidance to $4.40 to $4.50, up from $4.30 to $4.40.

Generated by AI

Sentiment

Of the messages about GMED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	2.7% -97.3	5.26% -93.97	94.22% +2.2
Bearish	—	97.3% +97.3	94.74% +93.97	5.78% -2.2

Bullish· Jan 8

Globus Medical reported record Q4 2025 revenue of $823M, a 25.2% YoY increase, and issued strong FY2026 revenue guidance of $3.18-3.22B.
The company's integration of the Nuvasive acquisition is progressing well, with preliminary Q4 2025 results exceeding expectations.
Analysts have raised their target prices for Globus Medical, with Barclays setting a new target of $118, Jefferies at $115, and RBC at $115.

Bearish· Feb 10

Globus Medical's stock has taken a significant hit, dipping 5.42% to $59.55.
Multiple analysts have downgraded Globus Medical's stock, including BTIG, Loop Capital, and Wells Fargo, citing concerns after the NuVasive deal.
The stock's technical indicators are also bearish, with Globus Medical falling below its 200-day moving average and exhibiting a wide range bar.

Generated by AI

Topics

Of the messages about GMED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	100%	14.05%
Technical Analysis	—	—	0%	28.04%
Earnings	—	—	0%	17.8%
Announcements	—	—	0%	33.26%
Controversies	—	—	0%	0%
Macro	—	—	0%	6.85%

Earnings· Nov 8

Globus Medical, Inc. ($GMED) reported earnings that met EPS estimates and beat revenue expectations.
$GMED is scheduled to release its earnings on November 8 after the market close.
The release of earnings has sparked interest in buying or selling the stock.

Analysts· Feb 10

Globus Medical's stock rating has been downgraded by multiple analysts, including Needham, Loop Capital, Truist, Wells Fargo, and BTIG.
The price target for Globus Medical's stock has been lowered by several analysts, with new targets ranging from $67 to $90.
Analysts have cited various challenges and concerns with Globus Medical, including the NuVasive deal and a "bunch of challenges" facing the company.

Announcements· Jan 8

Globus Medical (GMED) reported preliminary Q4 2025 sales of approximately $823M, a 25.2% YoY increase.
The company's full-year 2025 revenue was approximately $2.936B, a 16.5% YoY increase.
GMED's record Q4 sales and strong FY2026 revenue outlook ($3.18-3.22B) exceeded market estimates, driving a 9% stock price increase.

Generated by AI

Community

Of the messages about GMED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	16.9%
Newcomers	—	100%	100%	83.1%

Regulars· Jan 8

Globus Medical's Q4 2025 sales are expected to be approximately $823.2M, beating analyst estimates.
The company's preliminary results and strong 2026 guidance signal continued growth momentum, with its shares jumping in premarket trading.
Globus Medical's revenue growth has been impressive, with nearly 17% growth in the U.S. spinal business, surprising the market and analysts.

Newcomers· Jan 8

Newcomers are excited about Globus Medical's strong Q4 2025 results, with revenue up 25.2% YoY to a record ~$823M.
The company's acquisition of Nuvasive appears to be integrating well, and the preliminary Q4 2025 results have exceeded consensus estimates.
Globus Medical's strong Q4 2025 sales and upbeat FY26 guidance have led to a 9% stock price increase, with the stock continuing to trade higher despite some volatility.

Generated by AI

Globus Medical (GMED) has drawn investor attention after recent price moves left the stock down about 10% over the past month and roughly 5% lower over the past 3 months. Set against that short term pullback, Globus Medical’s 1 year total shareholder return of 32.5% and 3 year total shareholder return of 50.8% point to a very different picture from the recent 1 month share price decline of about 9.9% and 3 month share price drop of roughly 5.4%. This signals that momentum has cooled recently...

2d agoYahoo Finance

Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Globus Medical (GMED) Stock May Trade At A Discount On Earnings

12d agoYahoo Finance

BTIG reiterates Globus Medical stock rating amid Nevro concerns

13d agoInvesting.com

What Makes Globus Medical (GMED) a New Strong Buy Stock

Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

14d agoYahoo Finance

Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies

Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.

21d agoYahoo Finance

Also Discussed

Investors talking about GMED also mention

#	Name	Attention
1	Teleflex IncorporatedTFX	0%0
2	MasTec, Inc. Common StockMTZ	0.01%+0.01
3	CONMED CorporationCNMD	0%new
4	NUVA - NuVasive, Inc.	——
5	Tri-Continental CorporationTY	0%0
6	Stryker CorporationSYK	0%-0.01
7	Enel Chile S.A. ADRENIC	0.01%new
8	Ingevity CorporationNGVT	0%0
9	Intuitive Surgical Inc.ISRG	0%0
10	Edwards Lifesciences CorporationEW	0%0

Globus Medical Inc. Class A Common Stock

Healthcare
Medical Devices

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.

Website

Location

2560 General Armistead Avenue

Audubon, PA, 19403-5214

United States

Social

What share of all stock conversation is about GMED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Feb 24

Globus Medical (GMED) reported Q4 2025 earnings, beating revenue estimates with $826.4M sales and issuing full-year guidance of $3.2B.
The company's base business grew 10.6% and total revenue grew 26%, with GAAP EPS of $1.05, up 452.63% YoY.
GMED reaffirmed its full-year 2026 revenue guidance of $3.18B and updated its non-GAAP diluted EPS guidance to $4.40 to $4.50, up from $4.30 to $4.40.

Generated by AI

Sentiment

Of the messages about GMED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	2.7% -97.3	5.26% -93.97	94.22% +2.2
Bearish	—	97.3% +97.3	94.74% +93.97	5.78% -2.2

Bullish· Jan 8

Globus Medical reported record Q4 2025 revenue of $823M, a 25.2% YoY increase, and issued strong FY2026 revenue guidance of $3.18-3.22B.
The company's integration of the Nuvasive acquisition is progressing well, with preliminary Q4 2025 results exceeding expectations.
Analysts have raised their target prices for Globus Medical, with Barclays setting a new target of $118, Jefferies at $115, and RBC at $115.

Bearish· Feb 10

Globus Medical's stock has taken a significant hit, dipping 5.42% to $59.55.
Multiple analysts have downgraded Globus Medical's stock, including BTIG, Loop Capital, and Wells Fargo, citing concerns after the NuVasive deal.
The stock's technical indicators are also bearish, with Globus Medical falling below its 200-day moving average and exhibiting a wide range bar.

Generated by AI

Topics

Of the messages about GMED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	100%	14.05%
Technical Analysis	—	—	0%	28.04%
Earnings	—	—	0%	17.8%
Announcements	—	—	0%	33.26%
Controversies	—	—	0%	0%
Macro	—	—	0%	6.85%

Earnings· Nov 8

Globus Medical, Inc. ($GMED) reported earnings that met EPS estimates and beat revenue expectations.
$GMED is scheduled to release its earnings on November 8 after the market close.
The release of earnings has sparked interest in buying or selling the stock.

Analysts· Feb 10

Globus Medical's stock rating has been downgraded by multiple analysts, including Needham, Loop Capital, Truist, Wells Fargo, and BTIG.
The price target for Globus Medical's stock has been lowered by several analysts, with new targets ranging from $67 to $90.
Analysts have cited various challenges and concerns with Globus Medical, including the NuVasive deal and a "bunch of challenges" facing the company.

Announcements· Jan 8

Globus Medical (GMED) reported preliminary Q4 2025 sales of approximately $823M, a 25.2% YoY increase.
The company's full-year 2025 revenue was approximately $2.936B, a 16.5% YoY increase.
GMED's record Q4 sales and strong FY2026 revenue outlook ($3.18-3.22B) exceeded market estimates, driving a 9% stock price increase.

Generated by AI

Community

Of the messages about GMED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	16.9%
Newcomers	—	100%	100%	83.1%

Regulars· Jan 8

Globus Medical's Q4 2025 sales are expected to be approximately $823.2M, beating analyst estimates.
The company's preliminary results and strong 2026 guidance signal continued growth momentum, with its shares jumping in premarket trading.
Globus Medical's revenue growth has been impressive, with nearly 17% growth in the U.S. spinal business, surprising the market and analysts.

Newcomers· Jan 8

Newcomers are excited about Globus Medical's strong Q4 2025 results, with revenue up 25.2% YoY to a record ~$823M.
The company's acquisition of Nuvasive appears to be integrating well, and the preliminary Q4 2025 results have exceeded consensus estimates.
Globus Medical's strong Q4 2025 sales and upbeat FY26 guidance have led to a 9% stock price increase, with the stock continuing to trade higher despite some volatility.

Generated by AI

Globus Medical

Social

Feb 24

Bullish· Jan 8

Bearish· Feb 10

Earnings· Nov 8

Analysts· Feb 10

Announcements· Jan 8

Regulars· Jan 8

Newcomers· Jan 8

Globus Medical (GMED) Pulls Back Following Recent Weakness, Is The Stock Trading At A Discount?

Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

Globus Medical (GMED) Stock May Trade At A Discount On Earnings

BTIG reiterates Globus Medical stock rating amid Nevro concerns

What Makes Globus Medical (GMED) a New Strong Buy Stock

Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies

Also Discussed

Globus Medical Inc. Class A Common Stock

Company Information

Location

Globus Medical (GMED) Pulls Back Following Recent Weakness, Is The Stock Trading At A Discount?

Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

Globus Medical (GMED) Stock May Trade At A Discount On Earnings

BTIG reiterates Globus Medical stock rating amid Nevro concerns

What Makes Globus Medical (GMED) a New Strong Buy Stock

Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies

Also Discussed

Social

Feb 24

Bullish· Jan 8

Bearish· Feb 10

Earnings· Nov 8

Analysts· Feb 10

Announcements· Jan 8

Regulars· Jan 8

Newcomers· Jan 8